# EMBER (NCT04188548)

> A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

No report yet. It can be ordered.

- Drugs tested: imlunestrant; imlunestrant plus abemaciclib; imlunestrant plus everolimus
- Indication: ER+ advanced breast cancer and endometrial cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04188548
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Endometrial Cancer
- Interventions: LY3484356; Abemaciclib; Everolimus; Alpelisib; Trastuzumab; Aromatase Inhibitor (AI); Pertuzumab
- Enrollment: 379
- Primary outcome: Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities

## Indexed commentary on EMBER so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 15 YouTube videos
- 7 podcast episodes
- 4 posts on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ember-nct04188548

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04188548", "email": "<work email>"}; the inbox owner confirms by the emailed link.